Bausch Health Companies (BHC) Income from Continuing Operations (2009 - 2026)
Bausch Health Companies (BHC) reported Income from Continuing Operations of 1431000000.0 for Q1 2026, down 1563.95% on a YoY basis from 97749007.15 in Q1 2025, and down 1289.32% sequentially from 103000000.0 in Q4 2025.
Bausch Health Companies (BHC) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Bausch Health Companies (BHC) has 18 years of Income from Continuing Operations data on file, last reported at 1431000000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 1563.95% year-over-year to 1431000000.0; the trailing twelve-month figure through Mar 2026 stood at 1225000000.0 (down 1412.35% YoY), and the FY2025 full-year result was 120000000.0, up 266.67% from the prior year.
- Income from Continuing Operations slipped to 1431000000.0 in Q1 2026, from 103000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 403000000.0 in Q3 2022 to a low of 1431000000.0 in Q1 2026.
- A 5-year average of 129764705.88 and a median of 77000000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 12900.0% in 2025 and plunged 1563.95% in 2026, its largest moves.
- Tracing BHC's Income from Continuing Operations over 5 years: stood at 410000000.0 in 2022, then surged by 88.54% to 47000000.0 in 2023, then soared by 308.51% to 98000000.0 in 2024, then slumped by 205.1% to 103000000.0 in 2025, then plunged by 1289.32% to 1431000000.0 in 2026.
- Business Quant data shows BHC's Income from Continuing Operations at 1431000000.0 in Q1 2026, 103000000.0 in Q4 2025, and 181000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Bausch Health Companies | 1.66 Bn | 1.33 Bn | 2.52 Bn | -1.43 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.43 Bn |
| Dec 31, 2025 | -103.00 Mn |
| Sep 30, 2025 | 181.00 Mn |
| Jun 30, 2025 | 128.00 Mn |
| Mar 31, 2025 | -86.00 Mn |
| Dec 31, 2024 | 98.00 Mn |
| Sep 30, 2024 | -92.00 Mn |
| Jun 30, 2024 | -1.00 Mn |
| Mar 31, 2024 | -77.00 Mn |
| Dec 31, 2023 | -47.00 Mn |
| Sep 30, 2023 | -382.00 Mn |
| Jun 30, 2023 | 27.00 Mn |
| Mar 31, 2023 | -209.00 Mn |
| Dec 31, 2022 | -410.00 Mn |
| Sep 30, 2022 | 403.00 Mn |
| Jun 30, 2022 | -139.00 Mn |
| Mar 31, 2022 | -66.00 Mn |
| Dec 31, 2021 | 72.00 Mn |
| Sep 30, 2021 | 191.00 Mn |
| Jun 30, 2021 | -593.00 Mn |